Zacks: Analysts Expect Bristol-Myers Squibb Co (BMY) Will Post Earnings of $0.84 Per Share

Equities analysts expect Bristol-Myers Squibb Co (NYSE:BMY) to report earnings of $0.84 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Bristol-Myers Squibb’s earnings. The highest EPS estimate is $0.98 and the lowest is $0.73. Bristol-Myers Squibb also reported earnings of $0.84 per share during the same quarter last year. The firm is scheduled to report its next quarterly earnings results on Thursday, April 26th.

According to Zacks, analysts expect that Bristol-Myers Squibb will report full-year earnings of $3.24 per share for the current fiscal year, with EPS estimates ranging from $3.03 to $3.90. For the next year, analysts expect that the firm will post earnings of $3.91 per share, with EPS estimates ranging from $3.26 to $4.70. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Bristol-Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The firm had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 earnings per share.

A number of brokerages have issued reports on BMY. Barclays increased their price target on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. Jefferies Group downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target on the stock. in a research report on Monday, October 16th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 12th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Monday, January 29th. Finally, Leerink Swann increased their price target on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $65.58.

In other news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II bought 4,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the transaction, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Delphi Private Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $108,000. Massey Quick Simon & CO. LLC increased its holdings in shares of Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the last quarter. Horan Capital Advisors LLC. acquired a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $122,000. NuWave Investment Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $119,000. Finally, Tradewinds Capital Management LLC increased its holdings in shares of Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the last quarter. Institutional investors and hedge funds own 69.70% of the company’s stock.

Shares of Bristol-Myers Squibb (NYSE BMY) traded down $0.51 during mid-day trading on Tuesday, reaching $62.18. The company’s stock had a trading volume of 7,439,262 shares, compared to its average volume of 8,504,660. The stock has a market capitalization of $101,950.00, a P/E ratio of 105.39, a P/E/G ratio of 1.95 and a beta of 1.08. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb has a 52 week low of $51.52 and a 52 week high of $66.10.

The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.57%. The ex-dividend date was Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 271.19%.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect Bristol-Myers Squibb Co (BMY) Will Post Earnings of $0.84 Per Share” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2018/02/09/zacks-analysts-expect-bristol-myers-squibb-co-bmy-will-post-earnings-of-0-84-per-share.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit